Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874199 | 1.00 | IDO1 (0.35) | IDO1SMYD3CYP2C19NOTUMPSMB8 | |
| SCHEMBL19716170 | 1.00 | IDO1 (0.35) | IDO1SMYD3CYP2C19NOTUMPSMB8 | |
| SCHEMBL17874224 | 1.00 | IDO1 (0.35) | IDO1SMYD3CYP2C19NOTUMPSMB8 | |
| SCHEMBL19716161 | 1.00 | IDO1 (0.35) | IDO1SMYD3CYP2C19NOTUMPSMB8 | |
| SCHEMBL19716157 | 1.00 | IDO1 (0.35) | IDO1SMYD3CYP2C19NOTUMPSMB8 | |
| SCHEMBL17874200 | 1.00 | IDO1 (0.35) | IDO1SMYD3CYP2C19NOTUMPSMB8 | |
| SCHEMBL17887790 | 1.00 | IDO1 (0.35) | IDO1SMYD3CYP2C19NOTUMPSMB8 | |
| SCHEMBL19728242 | 0.85 | IDO1 (0.36) | IDO1CYP2C19NOTUMPSMB8PSMB9 | |
| SCHEMBL19728241 | 0.85 | IDO1 (0.36) | IDO1CYP2C19NOTUMPSMB8PSMB9 | |
| SCHEMBL19728245 | 0.85 | IDO1 (0.36) | IDO1CYP2C19NOTUMPSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016105468-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | CFTR, ABCC5, ABCD3 | IDO1 4553/4885SMYD3 4466/4885CYP2C19 3205/4885 |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | CFTR, ABCC5, ABCD3 | IDO1 4553/4885SMYD3 4466/4885CYP2C19 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.